 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...109110111112113114115116117118119...123124» |
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_769;
P3
Pembrolizumab, a programmed death 1 inhibitor, is approved for second-line treatment of advanced HCC in patients previously treated with sorafenib. N/A
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Biomarker, Review, Journal, PD(L)-1 Biomarker, IO Biomarker: Review article: systemic treatment of hepatocellular carcinoma. (Pubmed Central) - Oct 2, 2019
The tyrosine kinase inhibitors sorafenib (first line) and regorafenib (second line) have been approved for hepatocellular carcinoma, and the immune checkpoint inhibitor nivolumab obtained conditional approval for sorafenib-experienced patients in the United States. With lenvatinib in the first line, and cabozantinib and ramucirumab in sorafenib-experienced patients, three more targeted therapies reached their primary endpoint in phase III trials and may soon be added to the treatment armamentarium.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
You are going to have to listen to the episode. Just like BILCAP and lenvatinib in HCC, this won't be pretty. https://t.co/Hje5OmBs98 Probably will come out a week from tomorrow. This week is #FLAURA trial. (Twitter) - Oct 1, 2019
- | Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Trial completion date, Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker: KeyImPaCT: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (clinicaltrials.gov) - Sep 30, 2019
P2, N=318, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
With lenvatinib in the first line, and cabozantinib and ramucirumab in sorafenib-experienced patients, three more targeted therapies reached their primary endpoint in phase III trials and may soon be added to the treatment armamentarium. Trial completion date: May 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Jan 2023
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Safety and efficacy of 12 mg / day lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (HCC) and> 80 kg body weight in the REFLECT study (M6 / M7) - Sep 30, 2019 - Abstract #DGHO2019DGHO_1336;
In this post hoc analysis including patients of bw >80 kg receiving LEN 12 mg/d, efficacy and safety were similar to results in REFLECT. These results are consistent with the approved dose of 8 mg/d (bw < 60 kg) and 12 mg/d (bw ≥60 kg) of LEN in uHCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Post-progression therapy after lenvatinib first-line therapy: a post-hoc responder analysis of phase 3 REFLECT study in unresectable hepatocellular carcinoma (HCC) (M6 / M7) - Sep 30, 2019 - Abstract #DGHO2019DGHO_1332;
In REFLECT, one-third of patients randomized to first-line LEN received subsequent anticancer medication, including SOR, with a mOS of 21 mo. In this exploratory post hoc analysis of patients who responded to LEN and received any subsequent anticancer medication or SOR, mOS was 26 mo.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: First post IO data with pembro/lenvatinib combination in metastatic #kidneycancer. 64% partial responses. #ESMO19 #oncoalert (Twitter) - Sep 30, 2019
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib in metastatic thymic carcinoma #ESMO19 #LCSM (Twitter) - Sep 30, 2019
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Dr. Escudier even considered this combination (Pembro + Lenvatinib) a reasonable option in the 2nd line guidelines (his personal opinion). #ESMO19 (Twitter) - Sep 30, 2019
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: Dr. Escudier discusses the poster by Dr. Lee using Pembro + Lenvatinib in mRCC patients post PD-1 inhibition with/without Ipi or TKI. Very interesting ORR of 64%, much higher that I would have expected in patients that already received ICB. #ESMO19 (Twitter) - Sep 30, 2019
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: ESMO19 Insights >>> Published by Sarah Temkin in Twitter: RT @ShannonWestin: Toxicity from the combination of lenvatinib and pembrolizumab is common- 97% Adverse… https://t.co/hqz0rQq8E4 #ESMO19 #followthepatient #LucidQuest #oncology #cancer #insights #strategy #immunotherapy (Twitter) - Sep 29, 2019
- Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
CLINICAL OUTCOME OF TYROSINE KINASE INHIBITORS IN THE GERIATRIC PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2707;
There were no significant differences in OS, PFS and adverse events between geriatric and non- geriatric patients treated with TKIs. These results are reassuring as TKI therapies are acceptable in geriatric u-HCC patients with Child-Pugh A.
- Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
DIFFERENT MECHANISM OF ACTION OF REGORAFENIB AND LENVATINIB ON TOLL-LIKE RECEPTOR-SIGNALING PATHWAYS IN HUMAN HEPATOMA CELL LINES (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2519;
Lenvatinib has different actions on innate immunity from regorafenib. Innate immune response pathways play important roles in exerting effects of molecular-targeting drugs against HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
EXPLORATORY ANALYSIS OF BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOMES OF LENVATINIB IN HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2328;
This study demonstrates that RDI is an important predictive factor for longer PFS and confirms the importance of maintaining high RDI during lenvatinib treatment. This exploratory biomarker analysis identified a CAFs-signature associated with adverse events and RDI, which might improve management of lenvatinib treatment in HCC patients.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen, Visudyne (verteporfin) / Novartis
HEDGEHOG SIGNAL INHIBITORS INCREASE EFFICACY OF ANTI-CANCER DRUGS IN ORGANOID MODELS OF HUMAN HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2142;
By inhibiting the hedgehog signaling pathway, GANT61 can significantly enhance the efficacy of sorafenib and lenvatinib to suppress the viability of human primary HCC organoids. Therefore, while using "offensive drugs" in the clinic, we need to use stemness related drugs as "defensive drugs" to maximize the treatment efficacy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
IL-17 NEUTRALIZATION AMELIORATES THE EFFICACY OF ANTIANGIOGENIC TREATMENTS OF HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1979;
Altogether, these results showed in human HCC a positive correlation between the number of IL-17 infiltrating cells and the increased angiogenic activity. In addition, in vivo results strongly suggest that the use of anti-IL-17 neutralization as adjuvant treatment may significantly improve the efficacy of current antiangiogenic drugs.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
IMPACT OF LENVATINIB ON PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA REFRACTORY TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN CLINICAL PRACTICE (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1952;
Lenvatinib showed good clinical efficacy and tolerability for patients with unresectable HCC refractory to transcatheter arterial chemoembolization. As an alternative to transcatheter arterial chemoembolization, lenvatinib may be the first-choice treatment option for unresectable HCC; however, optimal management of adverse events and dose adjustments are needed.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
IN VIVO RAPID GENETIC SCREEN OF ONCOGENES INVOLVED IN THE SENSITIVITY OF MULTI-KINASE INHIBITORS IN HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1913;
Upon tumor identification by luciferase imaging, mice were treated with lenvatinib at 30mg/kg/day, sorafenib at 60mg/kg/day, or vehicle until moribund. Our novel high-throughput screen system successfully identified FGF19 as a susceptible marker of lenvatinib and MYC as its resistant marker.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB ALTERS TUMOR IMMUNE MICROENVIRONMENT FROM ‘COLD’ TO ‘HOT’ IN HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1786;
Our novel high-throughput screen system successfully identified FGF19 as a susceptible marker of lenvatinib and MYC as its resistant marker. In the syngeneic xenograft mouse model for HCC, lenvatinib apparently altered tumor immune microenvironment from 'cold' to 'hot'.The findings obtained from this study supportthe therapeutic concept of combining drugs targeting angiogenesis and immunology against immune ‘cold’ HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB AS AN INITIAL TREATMENT IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA BEYOND UP-TO-SEVEN CRITERIA AND CHILD-PUGH A LIVER FUNCTION: A MULTICENTER PROPENSITY-SCORE MATCHED STUDY (Hynes Convention Center, Ballroom BC) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1785;
In the syngeneic xenograft mouse model for HCC, lenvatinib apparently altered tumor immune microenvironment from 'cold' to 'hot'.The findings obtained from this study supportthe therapeutic concept of combining drugs targeting angiogenesis and immunology against immune ‘cold’ HCC. In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child-Pugh A liver function, who usually do not benefit from TACE, lenvatinib provides more favorable outcome than TACE.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD PRACTICE – MULTICENTER ANALYSISOF PROGNOSTIC FACTORS (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1784;
In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child-Pugh A liver function, who usually do not benefit from TACE, lenvatinib provides more favorable outcome than TACE. Good hepatic function (mALBI 1/2a) is the best indicator for good prognosis in patients receiving LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB IMPROVES PROGRESSION FREE SURVIVAL IN PATIENTS WITH INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA AFTER TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1783;
Moreover, we revealed that better indication of lenvatinib were HCC recurrence patients with “beyond the up-to-seven criteria and ALBI grade 1”. Thus, lenvatinib may prolong PFS in patients with recurrence of intermediate stage HCC after TACE.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB-INDUCED THYROID ABNORMALITIES IN UNRESECTABLE HEPATOCELLULAR CARCINOMA: PATIENTS WITH THYROID DYSFUNCTION HAD BETTER PROGNOSIS. (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1782;
Moreover, these thyroid conditions develop within the early period of treatment at a higher prevalence. Patients with thyroid dysfunction had better prognosis.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
OPTIMAL STRATEGY OF SWITCHING FROM TRANSARTERIAL CHEMOEMBOLIZATION TO MOLECULAR TARGETED THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1461;
Characteristics of patients at starting TKI were as follows: sorafenib/lenvatinib, 117/14; CP-A/B, 102/29; BCLC Stage 0-A/B/C, 8/67/56; median AFP, 114.9 ng/ml. HCC patients who experienced TACE had better outcome by starting TKI before progression to BCLC stage C. The TACE refractory patients need to be switched to TKI before development of EHS or VI.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
REAL WORLD EVIDENCE OF LENVATINIB IN ADVANCED HEPATOCELLULAR CARCINOMA: A MULTICENTER COHORT STUDY (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1176;
It was suggested that lenvatinib contributed to extending progression-free survival and overall survival. Therefore, lenvatinib demonstrated more anti-tumor activity and effective profile in patients with advanced HCC in our study.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
THE CORRELATION WITH EARLY TUMOR MARKER RESPONSE AND IMAGING RESPONSE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_873;
With lenvatinib therapy for HCC, the AFP level of most patients at 2 weeks declined, and the group AFP-sustained decreasing from 2 weeks to 4 weeks demonstrated a higher objective response. The group AFP-sustained decreasing and the group who maintained at least average 56 mg/2 weeks for 12weeks from lenvatinib treatment significantly associated with progression-free survival.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_699;
The group AFP-sustained decreasing and the group who maintained at least average 56 mg/2 weeks for 12weeks from lenvatinib treatment significantly associated with progression-free survival. We identified both tumor and blood FGFR4 level as independent predictors for lenvatinib responders.
- Nexavar (sorafenib) / Bayer, Amgen
UPREGULATION OF SECRETORY CLUSTERIN IN RESPONSE TO SORAFENIB LINKS TO ACQUIRED TREATMENT RESISTANCE OF HEPATOCELLULAR CARCINOMA. (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_674;
126 patients (pts) treated with sorafenib (SFN group), 9 pts with regorafenib (RFN group) and 22 pts with lenvatinib (LEN group) from Jun 2008 to Apr 2019, have been enrolled in this study. Clinical and in vitro observations describe a close relationship between sCLU upregulation and SFN resistance in HCC, and suggest that NR-index would be promising for early prediction of SFN effect.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Adverse events: Toxicity from the combination of lenvatinib and pembrolizumab is common- 97% Adverse events, 18.5% discontinuation, 72%dose interruption! aggressive toxicity management will be key #gyncsm #ESMO19 (Twitter) - Sep 29, 2019
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
FDA event: V. Makker presents data supporting the @US_FDA approval of lenvatinib and pembrolizumab in #endometrialcancer. Response rate of 36% in microsatellite stable tumors was durable #gyncsm #ESMO19 (Twitter) - Sep 29, 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. (Pubmed Central) - Sep 27, 2019
Clinical and in vitro observations describe a close relationship between sCLU upregulation and SFN resistance in HCC, and suggest that NR-index would be promising for early prediction of SFN effect. Our results suggest that maintaining an RDI ≥75% during the initial 8 weeks of lenvatinib treatment has a favorable impact on response.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Collaborative Review Leads to Concurrent Approval. (Pubmed Central) - Sep 27, 2019
Our results suggest that maintaining an RDI ≥75% during the initial 8 weeks of lenvatinib treatment has a favorable impact on response. In a regulatory first, the FDA has collaboratively reviewed a new cancer treatment with drug agencies in Canada and Australia, allowing for simultaneous approval of lenvatinib in combination with pembrolizumab for the treatment of recurrent endometrial carcinomas.
- || This result indicates high probability of success of these 2 ongoing ph3 studies in 1L HCC: COSMIC-312: cabozantinib + atezolizumab vs sorafenib LEAP-002 : lenvatinib + pembrolizumab vs lenvatinib (Twitter) - Sep 27, 2019
- |||| P3 data: This slide is underwhelming. HR for atezo/bev is 0.55...when compared to Atezo. This is likely not a good comparator arm given results with nivo/pembro -Also PFS for lenvatinib in REFLECT was 7.4 months. This may not be the homerun we were hoping for, will see in Phase 3 #hcc (Twitter) - Sep 27, 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Biomarker, Clinical, Journal: Clinical guidance for Radioiodine Refractory Differentiated Thyroid Cancer. (Pubmed Central) - Sep 26, 2019
In this review we examine the basic biology of radioiodine refractory disease, and discuss optimal treatment approaches, with specific focus on choice and timing of TKI treatment. This clinical field remains fluid, and directions for future research include exploring biomarkers and considering adjuvant TKI use in certain patient groups.
- | Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Review, Journal: Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. (Pubmed Central) - Sep 22, 2019
Nivolumab, cabozantinib, and lenvatinib plus everolimus have recently been approved as second-line treatments. The new agents discussed in this review increase the therapeutic options available and provide physicians with opportunities to individualize treatments for their patients, with a view to improving disease control and survival outcomes.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
ASSESSMENT OF LIVER FUNCTION USING ALBI SCORE IN PATIENTS TREATED WITH LENVATINIB FOR HEPATOCELLULAR CARCINOMA () - Sep 20, 2019 - Abstract #ILCA2019ILCA_325;
The new agents discussed in this review increase the therapeutic options available and provide physicians with opportunities to individualize treatments for their patients, with a view to improving disease control and survival outcomes. In cases where lenvatinib for HCC can be administered for 4 weeks or more, liver function may recover after it worsened once.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
FIRST-LINE COMBINATION THERAPY WITH LENVATINIB PLUS PEMBROLIZUMAB FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 3 LEAP-002 STUDY () - Sep 20, 2019 - Abstract #ILCA2019ILCA_315;
P3
Tumor imaging will be performed every 9 weeks on study. Adverse events (AEs) will be monitored throughout the treatment period and for 90 days after the last dose of study drug (120 days for serious AEs) and will be graded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
EFFICACY AND SAFETY OF LENVATINIB FOR UNRESECTAB HEPATOCELLULAR CARCINOMA IN CLINICAL PRACTICE () - Sep 20, 2019 - Abstract #ILCA2019ILCA_305;
Lenvatinib treatment was safe and showed a good response in clinical practice. The most common adverse event was fatigue, which may cause treatment withdrawal and result in a poor TTP; therefore, careful treatment of fatigue is necessary.
- Stivarga (regorafenib) / Bayer
CLINICAL OUTCOME AND BIOMARKERS IN JAPANESE PATIENTS TREATED WITH REGORAFENIB IN REAL WORLD PRACTICE () - Sep 20, 2019 - Abstract #ILCA2019ILCA_284;
Post-regorafenib therapies including lenvatinib would contribute to good prognosis. HFSR during sorafenib and regorafenib, and AFP decrease during regorafenib were significant predictors in regorafenib therapy.
- PHASE 3 (COSMIC-312) STUDY OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB VS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) WHO HAVE NOT RECEIVED PREVIOUS SYSTEMIC ANTICANCER THERAPY () - Sep 20, 2019 - Abstract #ILCA2019ILCA_198;
P3
VEGFR tyrosine kinase inhibitors sorafenib or lenvatinib are considered standard of care in first-line aHCC, while phase 3 trials of immune checkpoint inhibitors (ICIs) in first- and second- line aHCC are ongoing...Atezolizumab in combination with bevacizumab, an anti-VEGF antibody, has shown preliminary clinical activity in first-line aHCC (Pishvaian 2018)... N/A, as this is a Trial in Progress
- Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
COMPARISON OF SURVIVAL OUTCOMES FOR ADVANCED HEPATOCELLULAR CARCINOMA BEFORE AND DURING THE FIRST AND SECOND ERAS OF TYROSINE KINASE INHIBITORS () - Sep 20, 2019 - Abstract #ILCA2019ILCA_187;
Patients diagnosed with advanced stage HCC during the second term of TKI showed better survival outcomes than those diagnosed before and during the first term of TKIs. Multiple lines of TKI seem to markedly prolong OS for patients with advanced stage HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
REAL-WORLD APPROACHES TO TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WITH LENVATINIB IN JAPANESE PATIENTS: COMPLEMENTARY DATA FROM THE REFLECT TRIAL () - Sep 20, 2019 - Abstract #ILCA2019ILCA_169;
Despite the limitation with small number of patients with portal vein or/and bile duct invasion and massive intrahepatic lesions, the ORR of this subgroup of patients was similar to that of other patients. References: 1.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
SAFETY AND EFFICACY OF 12 MG/D LENVATINIB (LEN) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) AND BODYWEIGHT (BW) >80 KG IN REFLECT () - Sep 20, 2019 - Abstract #ILCA2019ILCA_159;
In this post hoc analysis including patients of bw >80 kg receiving LEN 12 mg/d, efficacy and safety were similar to results in REFLECT. These results are consistent with the approved dose of 8 mg/d (bw <60 kg) and 12 mg/d (bw ≥60 kg) of LEN in uHCC.
- Stivarga (regorafenib) / Bayer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
MATCHING-ADJUSTED INDIRECT COMPARISON OF CABOZANTINIB VERSUS REGORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA () - Sep 20, 2019 - Abstract #ILCA2019ILCA_152;
P3
In patients who received second-line treatment after sorafenib and were matched for BL characteristics, cabozantinib was associated with prolonged median PFS and OS compared with regorafenib, whereas regorafenib was associated with lower rates of diarrhea than cabozantinib. However, even after matching, bias may still occur in MAIC due to imbalance in unobserved factors, and it cannot replace a head-to-head randomized control trial.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
A POST HOC ANALYSIS OF NEUTROPHIL-LYMPHOCYTE RATIOS (NLR) IN THE REFLECT STUDY: FIRST-LINE LENVATINIB (LEN) OR SORAFENIB (SOR) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC). () - Sep 20, 2019 - Abstract #ILCA2019ILCA_151;
In this post hoc exploratory analysis of patients with uHCC from REFLECT, median NLR ≤3 was associated with better mOS compared with median NLR >3; regardless of treatment. LEN was associated with numerically higher mPFS, mOS, and a greater percent decrease in posttreatment NLR, compared with SOR.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
MECHANISMS OF IMMUNE-MEDIATED ANTITUMOR ACTIVITY OF COMBINED LENVATINIB AND PD-1 BLOCKADE IN MURINE MODELS OF HEPATOCELLULAR CARCINOMA () - Sep 20, 2019 - Abstract #ILCA2019ILCA_133;
LEN was associated with numerically higher mPFS, mOS, and a greater percent decrease in posttreatment NLR, compared with SOR. Combined therapy with lenvatinib and anti-PD-1 antibodies exerts anti-tumor activity by synergistically modulating effector T cells function in TME and through mutual regulation of tumor vessel normalization
- | Retrospective data, Journal: Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. (Pubmed Central) - Sep 19, 2019
According to current evidence, lenvatinib and apatinib had superior clinical effects for patients without previously systematic treatments, and regorafenib seemed to be more suitable for patients with previously targeted agent therapies. However, our conclusions still need more statistical validations, and more high-quality trials are expected.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
FDA event: FDA Approves Lenvatinib/Pembrolizumab Combo for Advanced Endometrial Cancer https://t.co/YrvrwfsN78 (Twitter) - Sep 18, 2019
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Biomarker, Review, Journal, IO Biomarker: The role of molecular enrichment on future therapies in hepatocellular carcinoma. (Pubmed Central) - Sep 18, 2019
Positive results in recent phase III clinical trials have confirmed the high value of anti-angiogenic therapies for HCC in both first (sorafenib and lenvatinib) and second line (regorafenib and cabozantinib) treatment modalities...Despite significant progress in our understanding of molecular subclasses of HCC, effective translation of the pre-clinical results into trial design is still missing. We here review important aspects of precision medicine approaches for HCC and delineate key milestones for clinical implementation.